Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost
Status:
Completed
Trial end date:
2020-09-13
Target enrollment:
Participant gender:
Summary
Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and
BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel
Group Design, Investigator-blind, Active-control, Randomized, Multi-center Study